NEW GUIDELINES for cervical cancer screening issued last year are fueling strong growth in the sales of Digene Corporation’s HPV test. For its fiscal second quarter that ended on December 31, 2004, Digene reported sales of $27.0 million. That’s a 28% increase from Digene’s sales of $21.1 million for its second quarter last year. HPV […]
- "Cytology Diagnostics"
Evolution in Pap Marketplace Shows Impact of New Guidelines
Sales of Digene’s HPV test grow rapidly, direct-to-consumer ads will start in March
- By Robert Michel
- > From the Volume XII No. 3 - February 14, 2005 Issue
